

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

2024 THIRD QUARTERLY REPORT

The Company and all the members of the board of directors confirm that all the information contained in this information disclosure is true, accurate and complete and that there is no false and misleading statement or material omission in this information disclosure.

This announcement is published in accordance with Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following is the 2024 third quarterly report of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**” or “**Hepalink**”, together with its subsidiaries referred to as the “**Group**”, “**we**” or “**our**”) for the nine months ended September 30, 2024 (the “**Reporting Period**”). Its financial report was prepared in accordance with the PRC Accounting Standards and Accounting Regulations for Business Enterprises and was unaudited.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
30 October, 2024

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.

IMPORTANT NOTICE:

1. The board of directors, supervisory committee, directors, supervisors and senior management of the Company undertake that the contents of the quarterly report are true, accurate and complete, without any false record, misrepresentation or material omission, and individually and jointly bear legal liabilities in this respect.
2. The person in charge of the Company, the person in charge of the accounting function and the person in charge of accounting department, declare that they guarantee the financial information in the quarterly report is true, accurate and complete.
3. Whether the third quarterly report has been audited
 Yes No

All directors attended the meeting of the board of directors held on October 30, 2024 at which the Company's third quarterly report for 2024 was considered and approved.

I. KEY FINANCIAL INFORMATION

(1) Major Accounting Information and Financial Indicators

Whether the Company is required to retroactively adjust or restate prior years' accounting information

Yes No

Currency: RMB Unit: Yuan

	The third quarter of 2024	Increase/decrease comparing the third quarter of 2024 with the same period last year	For the period from the beginning of the year to the end of the Reporting Period	Increase/decrease comparing the period from the beginning of the year to the end of the Reporting Period with the same period last year
Operating revenue	1,231,523,140.11	-8.80%	4,068,924,046.98	0.14%
Net profit attributable to the shareholders of the listed company	116,430,360.57	487.43%	780,113,811.99	444.89%
Net profit attributable to the shareholders of the listed company, net of extraordinary profits and losses	99,358,854.26	1,631.43%	428,828,218.59	402.43%
Net cash flows from operating activities	N/A	N/A	1,792,139,231.56	865.91%
Basic earnings per share	0.0794	488.15%	0.5317	444.77%
Diluted earnings per share	0.0794	488.15%	0.5317	444.77%
Weighted average return on net assets	0.97%	0.81%	6.43%	5.29%
	For the end of the Reporting Period	For the end of last year	Increase/decrease comparing the end of the Reporting Period with the end of last year	
Total assets	18,121,417,326.69	19,203,415,131.24	-5.63%	
Owners' equity attributable to the shareholders of the listed company	12,140,384,965.66	11,913,149,195.32	1.91%	

(2) Items and Amounts of Extraordinary Profits and Losses

Applicable

Not Applicable

Currency: RMB Unit: Yuan

Items	Amount for the third quarter of 2024	Amount for the period from the beginning of the year to the end of the Reporting Period	Description
Gain or loss on disposal of non-current assets (inclusive of asset impairment allowance write-off)	1,589,559.35	272,978,153.50	Includes investment gains totalling RMB272,018,109.67 arising from the disposal of equity interests in HighTide Therapeutics, Inc. (“HighTide”) and the change in accounting method, and gains and losses totalling RMB960,043.83 arising from the disposal of other non-current assets.
Government grant included in profit or loss (other than those which are closely related to the normal operation of the Company, in line with national policies and regulations, granted in accordance with specified standards, and have a continuous impact on the profit or loss of the Company)	5,108,928.12	9,392,939.82	
Gain or loss on fair value changes arising from financial assets and financial liabilities held by non-financial entities, and gain or loss arising from the disposal of financial assets and financial liabilities, except for effective hedging transactions that are related to the normal operation of the Company	14,580,703.39	136,141,968.52	Includes gains and losses on fair value changes arising from financial products, derivative financial assets, convertible bonds, equity investments and fund investments totalling RMB-98,345,865.94, and investment gains from disposal of and acquired during the holding of financial products, equity investments and fund investments totalling RMB234,487,834.46.

Items	Amount for the third quarter of 2024	Amount for the period from the beginning of the year to the end of the Reporting Period	Description
Other non-operating income and expense apart from the aforesaid items	-968,365.59	-16,614,857.92	Includes a telecommunication fraud suffered by Techdow Pharma Italy S.R.L. (“ Techdow Italy ”), a wholly-owned subsidiary of the Company. This involves a fraudulent transfer of RMB15,559,523.79 in 2024 which was included in non-operating expenses for 2024.
Less: Effect of income tax	3,234,938.45	50,604,178.40	
Effect of minority interest (after tax)	4,380.51	8,432.12	
Total	17,071,506.31	351,285,593.40	—

Other profit and loss items that meet the definition of extraordinary profit and losses are as follows:

Applicable Not Applicable

The Company has no other specific profit and loss items that meet the definition of extraordinary profit and loss.

Explanation given for defining an extraordinary profit and loss item as listed in the “Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Their Securities to the Public – Extraordinary Profit and Loss” as a recurring profit and loss item

Applicable Not Applicable

The Company has not defined any extraordinary profit and loss item as listed in the “Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Their Securities to the Public – Extraordinary Profit and Loss” as a recurring profit and loss item.

(3) Changes in Key Accounting Data and Financial Indicators and Reasons

Applicable Not Applicable

1. Balance sheet items

Currency: RMB Unit: Yuan

Items	As at the end of the Reporting Period	As at the end of last year	Year-on-year increase/decrease	Reasons for changes
Financial assets held for trading	836,795,932.21	414,183,797.99	102.03%	Mainly attributable to the increase in purchases of wealth management products during the Reporting Period
Bills receivable	1,043,432.92	3,181,945.34	-67.21%	Mainly attributable to the decrease in bills receivable during the Reporting Period
Other current assets	247,434,353.18	177,922,857.76	39.07%	Mainly attributable to the increase in deductible VAT during the Reporting Period
Long-term receivables	517,251.49	950,953.45	-45.61%	Mainly attributable to the decrease in long-term receivables during the Reporting Period
Long-term equity investment	496,236,843.73	1,004,045,899.43	-50.58%	Mainly as a result of the disposal of equity interests in HighTide and fund investments during the Reporting Period
Construction in progress	622,665,301.62	468,721,277.73	32.84%	Mainly attributable to the increase in new production lines
Other non-current assets	26,429,348.21	121,836,377.22	-78.31%	Mainly as a result of the recovery of bond issue deposits
Non-current assets due within one year	1,110,059,827.40	1,781,636,658.23	-37.69%	Mainly attributable to the settlement of matured bonds during the Reporting Period
Long-term borrowings	1,192,542,910.05	1,810,021,034.38	-34.11%	Mainly attributable to the decrease in borrowings during the Reporting Period
Other comprehensive income	92,864,185.07	158,456,124.46	-41.39%	Mainly attributable to the fluctuations in exchange rates during the Reporting Period

2. Income statement items

Currency: RMB Unit: Yuan

Items	From the beginning of the year to the end of the Reporting Period	Same period last year	Year-on-year increase/decrease	Reasons for changes
Selling expenses	280,983,594.46	402,920,606.39	-30.26%	Mainly attributable to the decrease in marketing expenses during the Reporting Period
Other income	9,392,939.82	20,383,283.61	-53.92%	Mainly attributable to the decrease in government grants during the Reporting Period
Investment income (losses are represented by "-")	416,440,156.93	-274,834,971.73	251.52%	Mainly as a result of the disposal of equity interests in HighTide and fund investments during the Reporting Period
Gain on fair value changes (losses are represented by "-")	-98,345,865.94	37,143,775.77	-364.77%	Mainly attributable to the year-on-year decrease in gain on fair value changes of financial assets during the Reporting Period
Credit impairment losses (losses are represented by "-")	11,001,914.40	-3,097,694.49	455.16%	Mainly attributable to the decrease in credit impairment losses on trade and other receivables during the Reporting Period
Impairment losses on assets (losses are represented by "-")	28,234,151.33	5,551,276.16	408.61%	Mainly attributable to the decrease in impairment losses on assets during the Reporting Period
Gain on disposal of assets (losses are represented by "-")	620,158.53	-549,392.43	212.88%	Mainly attributable to the increase in gain on disposal of assets during the Reporting Period
Operating profit	903,477,746.40	178,819,355.74	405.25%	Mainly attributable to the decrease in expenses and the increase in investment income during the Reporting Period

Items	From the beginning of the year to the end of the Reporting Period	Same period last year	Year-on-year increase/decrease	Reasons for changes
Non-operating income	944,567.55	6,458,415.02	-85.37%	Mainly attributable to the absence of insurance claims during the Reporting Period
Non-operating expenses	17,219,540.17	4,102,908.74	319.69%	Mainly attributable to the increase in non-operating expenses during the Reporting Period as a result of a telecommunication fraud suffered by Techdow Italy.
Total profit	887,202,773.78	181,174,862.02	389.69%	Refer to the analysis on reasons for changes in operating profit
Income tax expense	108,143,486.10	39,289,379.06	175.25%	Mainly attributable to the year-on-year increase in total profit for the Reporting Period and the year-on-year increase in income tax expense
Net profit	779,059,287.68	141,885,482.96	449.08%	Refer to the analysis on reasons for changes in operating profit
Net profit attributable to owners of the parent company	780,113,811.99	143,170,121.26	444.89%	Refer to the analysis on reasons for changes in operating profit

3. Cash flow items

Unit: Yuan

Items	For the Reporting Period	Same period last year	Year-on-year increase/decrease	Reasons for changes
Net cash flows from operating activities	1,792,139,231.56	-233,988,970.92	865.91%	Mainly attributable to the higher year-on-year increase in cash received from the sale of goods and rendering of services than the year-on-year decrease in cash paid for purchasing goods and receiving services during the Reporting Period, and that net cash flows from operating activities showed a positive trend compared with the same period last year
Net cash flows from investing activities	-226,221,859.93	1,312,338,280.10	-117.24%	Mainly attributable to fewer investment activities in wealth management products during the Reporting Period and a significant decrease in both recovery and investment amounts
Net cash flows from financing activities	-1,345,954,669.90	-672,098,505.03	-100.26%	Mainly attributable to the maturity and repayment of corporate bonds during the Reporting Period which resulted in a year-on-year decrease in net borrowing

II. INFORMATION OF THE SHAREHOLDERS

- (1) **Table regarding the total number of ordinary shareholders, the number of shareholders of preferred shares with restored voting right and the shareholding of top ten shareholders**

Unit: Share(s)

Total number of ordinary shareholders as at the end of the Reporting Period		Total number of shareholders of preferred shares (if any) with restored voting right as at the end of the Reporting Period				
27,499		0				
Shareholding of top ten Shareholders (excluding shares lent through refinancing)						
Name of shareholder	Nature of shareholder	Shareholding percentage	Number of shares held	Number of shares held subject to selling restrictions	Pledged, marked or frozen	
					Share status	Number
Shenzhen Leren Technology Co., Ltd.	Domestic non-state-owned legal person	32.31%	474,029,899	0	N/A	0
Xiamen Jintiantu Investment Partnership (Limited Partnership)	Domestic non-state-owned legal person	27.81%	408,041,280	0	N/A	0
HKSCC NOMINEES LIMITED (Note 1)	Foreign legal person	15.00%	220,037,480	0	N/A	0
Xiamen Shuidi Shichuan Investment Partnership (Limited Partnership)	Domestic non-state-owned legal person	3.16%	46,425,600	0	N/A	0
Xiamen Feilaishi Investment Co., Ltd.	Domestic non-state-owned legal person	2.75%	40,320,000	0	N/A	0
Hong Zejun	Domestic natural person	2.73%	40,000,000	0	N/A	0

Shareholding of top ten Shareholders (excluding shares lent through refinancing)						
Name of shareholder	Nature of shareholder	Shareholding percentage	Number of shares held	Number of shares held subject to selling restrictions	Pledged, marked or frozen	
					Share status	Number
Shenzhen Hepalink Pharmaceutical Co., Ltd. – Employee Share Scheme II	Others	1.03%	15,118,035	0	N/A	0
Hong Kong Securities Clearing Company Limited	Foreign legal person	0.49%	7,219,056	0	N/A	0
Lu Yang	Domestic natural person	0.38%	5,550,000	0	N/A	0
Shenzhen Hepalink Pharmaceutical Co., Ltd. – Employee Share Scheme III	Others	0.26%	3,886,264	0	N/A	0
Shareholding of top ten shareholders not subject to selling restrictions (excluding shares lent through refinancing and locked up shares of senior management)						
Name of shareholder	Number of shares held not subject to selling restrictions	Type and number of shares				
		Share type	Number			
Shenzhen Leren Technology Co., Ltd.	474,029,899	RMB ordinary shares	474,029,899			
Xiamen Jintiantu Investment Partnership (Limited Partnership)	408,041,280	RMB ordinary shares	408,041,280			
HKSCC NOMINEES LIMITED (Note 1)	220,037,480	Overseas listed foreign shares	220,037,480			
Xiamen Shuidi Shichuan Investment Partnership (Limited Partnership)	46,425,600	RMB ordinary shares	46,425,600			
Xiamen Feilaishi Investment Co., Ltd.	40,320,000	RMB ordinary shares	40,320,000			
Hong Zejun	40,000,000	RMB ordinary shares	40,000,000			

Shareholding of top ten shareholders not subject to selling restrictions (excluding shares lent through refinancing and locked up shares of senior management)			
Name of shareholder	Number of shares held not subject to selling restrictions	Type and number of shares	
		Share type	Number
Shenzhen Hepalink Pharmaceutical Co., Ltd. – Employee Share Scheme II	15,118,035	RMB ordinary shares	15,118,035
Hong Kong Securities Clearing Company Limited	7,219,056	RMB ordinary shares	7,219,056
Lu Yang	5,550,000	RMB ordinary shares	5,550,000
Shenzhen Hepalink Pharmaceutical Co., Ltd. – Employee Share Scheme III	3,886,264	RMB ordinary shares	3,886,264
Explanation on the connected relationship or acting in concert relationship among the above shareholders	<p>The shareholders (partners) of Shenzhen Leren Technology Co., Ltd. and Xiamen Jintiantu Investment Partnership (Limited Partnership) are Li Li (李鋸) and Li Tan (李坦), the shareholder of Xiamen Feilaishi Investment Co., Ltd. is Li Li, and the partners of Xiamen Shuidi Shichuan Investment Partnership (Limited Partnership) are Shan Yu (單宇) and Li Tan. Li Li and Li Tan are the spouse of each other. Shan Yu is the elder brother of Li Tan. Shan Yu has participated in Employee Share Scheme II of the Company with a participation share of 38.88% of that Employee Share Scheme. Save for the aforesaid information, the Company is not aware of any related relationship among the other top 10 shareholders or parties acting in concert.</p> <p>Note 1: HKSCC NOMINEES LIMITED's shares are held on behalf of multiple clients.</p>		
Explanation on the top ten shareholders' participation in financing and securities lending business (if any)	<p>Among the top ten ordinary shareholders, Shenzhen Leren Technology Co., Ltd. held 374,029,899 shares through ordinary securities accounts, and held 100,000,000 shares through its client credit transaction guarantee securities account with CITIC Securities Co., Ltd., representing an actual total shareholding of 474,029,899 shares; Hong Zejun held 3,000,000 shares through ordinary securities accounts, and held 37,000,000 shares through its client credit transaction guarantee securities account with China Galaxy Securities Co., Ltd., representing an actual total shareholding of 40,000,000 shares; Lu Yang held 5,000,000 shares through ordinary securities accounts, and held 550,000 shares through its client credit transaction guarantee securities account with China CICC Wealth Management Securities Company Limited, representing an actual total shareholding of 5,550,000 shares.</p>		

Shares lent through refinancing business participated by the shareholders holding 5% or above shares, the top 10 shareholders and the top 10 shareholders holding tradable shares not subject to selling restrictions

Applicable Not Applicable

Changes in the top 10 shareholders and the top 10 shareholders holding tradable shares not subject to selling restrictions due to the shares lent and returned through refinancing as compared with the corresponding period last year

Applicable Not Applicable

(2) Table regarding the total number of shareholders of preferred shares of the Company and shareholdings of the top ten shareholders of preferred shares

Applicable Not Applicable

III. OTHER IMPORTANT EVENTS

Applicable Not Applicable

IV. QUARTERLY FINANCIAL STATEMENTS

(1) Financial Statements

1. Consolidated Balance Sheet

Prepared by: Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

September 30, 2024

Currency: RMB Unit: Yuan

Items	Ending balance	Beginning balance
Current assets:		
Cash at bank and on hand	2,242,888,528.02	1,851,642,224.58
Provision of settlement fund		
Placements with banks and other financial institutions		
Financial assets held for trading	836,795,932.21	414,183,797.99
Derivative financial assets		
Bills receivable	1,043,432.92	3,181,945.34
Accounts receivable	1,198,542,608.72	1,260,401,844.95
Receivables financing		
Prepayments	130,263,435.97	111,086,167.01
Premiums receivable		
Reinsurance accounts receivable		
Reinsurance contract reserves receivable		
Other receivables	91,362,066.01	120,428,285.38
Including: Interests receivable		
Dividends receivable		
Financial assets held under resale agreements		
Inventories	5,612,822,105.25	6,654,110,787.81
Including: Data resource		
Contract assets	10,830,234.09	10,946,613.44
Assets held for sale		
Non-current assets due within one year		
Other current assets	247,434,353.18	177,922,857.76
Total current assets	10,371,982,696.37	10,603,904,524.26

Items	Ending balance	Beginning balance
Non-current assets:		
Loans and advances to customers		
Debt investments		
Other debt investments		
Long-term receivables	517,251.49	950,953.45
Long-term equity investment	496,236,843.73	1,004,045,899.43
Other equity instruments investments	581,872,397.18	503,564,633.87
Other non-current financial assets	802,805,425.42	1,006,366,852.38
Investment properties		
Fixed assets	1,916,208,480.62	2,048,413,853.70
Construction in progress	622,665,301.62	468,721,277.73
Biological assets for production		
Oil and gas assets		
Right-of-use assets	94,295,118.03	117,089,646.40
Intangible assets	429,911,417.22	474,571,881.15
Including: Data resource		
Development costs	19,807,286.98	18,644,260.16
Including: Data resource		
Goodwill	2,297,684,725.26	2,322,375,146.78
Long-term deferred expenses	189,848,595.24	192,426,619.85
Deferred income tax assets	271,152,439.32	320,503,204.86
Other non-current assets	26,429,348.21	121,836,377.22
Total non-current assets	7,749,434,630.32	8,599,510,606.98
Total assets	18,121,417,326.69	19,203,415,131.24

Items	Ending balance	Beginning balance
Current liabilities:		
Short-term borrowings	1,943,995,355.97	1,880,741,215.42
Borrowing from the central bank		
Placements from banks and other financial institutions		
Financial liabilities held for trading	397,853.81	388,065.76
Derivative financial liabilities		
Bills payable		
Accounts payable	343,997,903.60	302,222,539.44
Receipts in advance		
Contract liabilities	256,391,155.39	366,166,947.59
Financial assets sold under repurchase agreements		
Receipt of deposits and deposits from other banks		
Customer deposits for trading in securities		
Customer deposits for undertaking securities		
Employee remuneration payable	108,572,128.03	153,714,619.30
Taxes payable	217,575,592.20	195,735,667.31
Other payables	360,301,848.97	305,574,589.10
Including: Interests payable		
Dividends payable		
Fees and commissions payable		
Reinsurance accounts payable		
Liabilities held for sale		
Non-current liabilities due within one year	1,110,059,827.40	1,781,636,658.23
Other current liabilities		
Total current liabilities	4,341,291,665.37	4,986,180,302.15

Items	Ending balance	Beginning balance
Non-current liabilities:		
Provision for insurance contracts		
Long-term borrowings	1,192,542,910.05	1,810,021,034.38
Bonds payable		
Including: Preferred shares		
Perpetual bonds		
Lease liabilities	63,722,638.48	90,417,128.71
Long-term payables	451,644.76	409,705.12
Long-term employee remuneration payable	32,458,576.65	35,272,506.82
Contingent liabilities	9,639,657.07	9,743,242.74
Deferred income	27,206,926.14	30,425,907.80
Deferred income tax liabilities	239,574,569.57	252,567,586.70
Other non-current liabilities		
Total non-current liabilities	1,565,596,922.72	2,228,857,112.27
Total liabilities	5,906,888,588.09	7,215,037,414.42
Owners' equity:		
Share capital	1,467,296,204.00	1,467,296,204.00
Other equity instruments		
Including: Preferred shares		
Perpetual bonds		
Capital reserves	5,868,788,275.98	6,356,074,378.24
Less: Treasury stock		
Other comprehensive income	92,864,185.07	158,456,124.46
Special reserves		
Surplus reserves	545,376,458.31	545,376,458.31
Provision for general risks		
Retained earnings	4,166,059,842.30	3,385,946,030.31
Total equity attributable to owners of the parent company	12,140,384,965.66	11,913,149,195.32
Non-controlling interest	74,143,772.94	75,228,521.50
Total owners' equity	12,214,528,738.60	11,988,377,716.82
Total liabilities and owners' equity	18,121,417,326.69	19,203,415,131.24

Legal representative:
Li Li

Person in charge of
accounting function:
Chen Juan

Person in charge of
accounting firm:
Chen Juan

2. Consolidated Income Statement from the beginning of the year to the end of the Reporting Period

Currency: RMB Unit: Yuan

Items	Amount for current period	Amount for previous period
I. Total operating revenue	4,068,924,046.98	4,063,233,063.48
Including: Operating revenue	4,068,924,046.98	4,063,233,063.48
Interest income		
Insurance premiums earned		
Fee and commission income		
II. Total operating costs	3,532,789,755.65	3,669,009,984.63
Including: Operating costs	2,717,925,174.12	2,720,675,046.08
Interest expenses		
Fee and commission expenses		
Insurance withdrawal payment		
Net claims expenses		
Net provisions withdrew for insurance liability contract		
Insurance policy dividend paid		
Reinsurance costs		
Taxes and surcharges	11,943,049.71	12,802,583.40
Selling expenses	280,983,594.46	402,920,606.39
Administration expenses	309,001,809.85	306,237,517.82
Research and development expenses	129,976,981.05	152,223,825.20
Finance costs	82,959,146.46	74,150,405.74
Including: Interest expenses	110,546,655.49	172,185,286.54
Interest income	33,289,597.63	34,032,251.07
Add: Other income	9,392,939.82	20,383,283.61
Investment income (losses are represented by “-”)	416,440,156.93	-274,834,971.73
Including: Investment income from associates and joint ventures	-90,065,787.20	-283,240,300.17
Revenue from derecognition of financial assets measured at amortised cost		

Items	Amount for current period	Amount for previous period
Exchange gains (losses are represented by “-”)		
Gains on net exposure hedges (losses are represented by “-”)		
Gains on fair value changes (losses are represented by “-”)	-98,345,865.94	37,143,775.77
Credit impairment losses (losses are represented by “-”)	11,001,914.40	-3,097,694.49
Asset impairment losses (losses are represented by “-”)	28,234,151.33	5,551,276.16
Gains from disposal of assets (losses are represented by “-”)	620,158.53	-549,392.43
III. Operating profit (losses are represented by “-”)	903,477,746.40	178,819,355.74
Add: Non-operating income	944,567.55	6,458,415.02
Less: Non-operating expenses	17,219,540.17	4,102,908.74
IV. Total profit (total losses are represented by “-”)	887,202,773.78	181,174,862.02
Less: Income tax expense	108,143,486.10	39,289,379.06
V. Net profit (net losses are represented by “-”)	779,059,287.68	141,885,482.96
(I) Classified by going concern basis		
1. Net profit from continuing operations (net losses are represented by “-”)	779,059,287.68	141,885,482.96
2. Net profit from discontinued operations (net losses are represented by “-”)		
(II) Classification by ownership of the equity		
1. Net profit attributable to shareholders of the parent company (net losses are represented by “-”)	780,113,811.99	143,170,121.26
2. Profit or loss attributable to non-controlling interests (net losses are represented by “-”)	-1,054,524.31	-1,284,638.30
VI. Other comprehensive income, net of tax	-65,622,163.64	101,092,675.13
Other comprehensive income attributable to owners of the parent company, net of tax	-65,591,939.39	101,005,511.82
(I) Other comprehensive income that cannot be reclassified to profit or loss	-19,598,736.76	-3,008,947.26
1. Changes arising from re-measurement of defined benefit plans	4,032,676.37	2,251,161.67
2. Other comprehensive income that cannot be transferred into profit or loss under equity method		

Items	Amount for current period	Amount for previous period
3. Changes in fair value of other equity instruments investments	-23,631,413.13	-5,260,108.93
4. Changes in fair value of credit risks of the enterprise		
5. Others		
(II) Other comprehensive income to be reclassified into profit or loss	-45,993,202.63	104,014,459.08
1. Other comprehensive income that can be transferred into profit or loss under equity method	14,905,179.57	180,002.99
2. Changes in fair value of other debt investments		
3. Financial assets reclassified into other comprehensive income		
4. Credit impairment provision for other debt investments		
5. Cash flow hedging reserve		
6. Exchange differences on translation of financial statements denominated in foreign currencies	-60,898,382.20	103,834,456.09
7. Others		
Other comprehensive income attributable to non-controlling interests, net of tax	-30,224.25	87,163.31
VII. Total comprehensive income	713,437,124.04	242,978,158.09
(I) Total comprehensive income attributable to owners of the parent company	714,521,872.60	244,175,633.08
(II) Total comprehensive income attributable to non-controlling interests	-1,084,748.56	-1,197,474.99
VIII. Earnings per share:		
(I) Basic earnings per share	0.5317	0.0976
(II) Diluted earnings per share	0.5317	0.0976

Net profit realised by the combined party before the combination in respect of business combination under common control during the current period: RMB0.00, net profit realised by the combined party during the previous period: RMB0.00.

Legal representative:
Li Li

Person in charge of
accounting function:
Chen Juan

Person in charge of
accounting firm:
Chen Juan

3. Consolidated Cash Flow Statement from the beginning of the year to the end of the Reporting Period

Currency: RMB Unit: Yuan

Items	Amount for current period	Amount for previous period
I. Cash flows from operating activities:		
Cash received from the sale of goods and rendering of services	4,299,443,691.71	4,603,550,675.54
Net increase in customers and interbank deposits		
Net increase in borrowing from the central bank		
Net increase in placement from other financial institutions		
Cash received from premiums under original insurance contract		
Net cash received from reinsurance business		
Net increase in deposits of policy holders and investment		
Cash received from interest, fee and commissions		
Net increase in placements from banks and other financial institutions		
Net increase in cash received from repurchase operation		
Net cash received from securities trading agency services		
Refunds of taxes received	182,824,769.96	206,974,609.19
Cash received from other related operating activities	135,392,351.53	47,790,265.82
Sub-total of cash inflows from operating activities	4,617,660,813.20	4,858,315,550.55
Cash paid for purchasing goods and receiving services	1,477,390,948.62	3,633,091,884.41
Net increase in loans and advances to customers		
Net increase in deposits with central bank and interbank		
Cash paid for compensation payments under original insurance contract		
Net increase in placements with banks and other financial institutions		
Cash paid for interest, fees and commissions		
Cash paid for insurance policy dividend		
Cash paid to and on behalf of employees	557,639,994.99	673,352,520.02
Cash paid for all types of taxes	279,418,398.98	210,215,294.50
Cash paid for other related operating activities	511,072,239.05	575,644,822.54
Sub-total of cash outflows from operating activities	2,825,521,581.64	5,092,304,521.47
Net cash flows from operating activities	1,792,139,231.56	-233,988,970.92

Items	Amount for current period	Amount for previous period
II. Cash flows from investment activities:		
Cash received from realisation of investments	1,148,921,549.70	1,494,880,389.45
Cash received from investment income	320,917,358.16	32,344,822.97
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	2,794,335.48	2,323,756.31
Net cash received from disposal of subsidiaries and other operating entities		
Cash received from other related investment activities	42,924,953.20	771,783,056.20
Sub-total of cash inflows from investing activities	1,515,558,196.54	2,301,332,024.93
Cash paid on purchase of fixed assets, intangible assets and other long-term assets	140,274,569.87	274,837,032.45
Cash paid for investments	1,444,854,036.60	683,038,740.26
Net increase in pledged loans		
Net cash paid for the acquisition of subsidiaries and other operating entities		
Cash paid for other related investment activities	156,651,450.00	31,117,972.12
Sub-total of cash outflows from investing activities	1,741,780,056.47	988,993,744.83
Net cash flows from investing activities	-226,221,859.93	1,312,338,280.10
III. Cash flows from financing activities:		
Cash received from capital contributions	192,339.71	
Including: Cash received by subsidiaries from capital contributions by non-controlling interests		
Cash received from borrowings	2,281,222,475.16	3,557,251,571.62
Cash received from other related financing activities	39,543,200.58	150,342,810.61
Sub-total of cash inflows from financing activities	2,320,958,015.45	3,707,594,382.23
Cash paid on repayment of debts	3,503,928,512.63	4,097,326,290.58
Cash paid on distribution of dividends, profits or settlement of interest	133,240,515.41	250,602,018.90
Including: Dividend and profit paid to non-controlling interests by subsidiaries		
Cash paid for other related financing activities	29,743,657.31	31,764,577.78
Sub-total of cash outflows from financing activities	3,666,912,685.35	4,379,692,887.26
Net cash flows from financing activities	-1,345,954,669.90	-672,098,505.03

Items	Amount for current period	Amount for previous period
IV. Effect of fluctuations in exchange rates on cash and cash equivalents	9,871,785.63	31,821,093.12
V. Net increase in cash and cash equivalents	229,834,487.36	438,071,897.27
Add: Balance of cash and cash equivalents at the beginning of the period	1,765,644,711.88	1,319,707,185.95
VI. Balance of cash and cash equivalents at the end of the period	1,995,479,199.24	1,757,779,083.22

(2) Adjustments to the opening financial statements of the year of initial implementation of the new accounting standards for the first time from 2024 onwards

Applicable Not Applicable

(3) Audit Report

Whether the third quarterly report has been audited

Yes No

The third quarterly report of the Company has not been audited.

Board of Directors of Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
October 31, 2024